Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q82711662)
Watch
English
Bevacizumab and breast cancer: the E2100 outlier
scientific article published on 01 December 2010
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PubMed publication ID
21126685
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21126685%20AND%20SRC:MED&resulttype=core&format=json
retrieved
17 January 2020
title
Bevacizumab and breast cancer: the E2100 outlier
(English)
1 reference
stated in
Europe PubMed Central
PubMed publication ID
21126685
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21126685%20AND%20SRC:MED&resulttype=core&format=json
retrieved
17 January 2020
main subject
bevacizumab
1 reference
based on heuristic
inferred from title
author
Julia Wilkerson
series ordinal
2
1 reference
stated in
Europe PubMed Central
PubMed publication ID
21126685
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21126685%20AND%20SRC:MED&resulttype=core&format=json
retrieved
17 January 2020
Tito Fojo
series ordinal
1
object named as
Tito Fojo
1 reference
stated in
Europe PubMed Central
PubMed publication ID
21126685
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21126685%20AND%20SRC:MED&resulttype=core&format=json
retrieved
17 January 2020
publication date
1 December 2010
1 reference
stated in
Europe PubMed Central
PubMed publication ID
21126685
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21126685%20AND%20SRC:MED&resulttype=core&format=json
retrieved
17 January 2020
published in
Lancet Oncology Commission
1 reference
stated in
Europe PubMed Central
PubMed publication ID
21126685
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21126685%20AND%20SRC:MED&resulttype=core&format=json
retrieved
17 January 2020
volume
11
1 reference
stated in
Europe PubMed Central
PubMed publication ID
21126685
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21126685%20AND%20SRC:MED&resulttype=core&format=json
retrieved
17 January 2020
issue
12
1 reference
stated in
Europe PubMed Central
PubMed publication ID
21126685
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21126685%20AND%20SRC:MED&resulttype=core&format=json
retrieved
17 January 2020
page(s)
1117-1119
1 reference
stated in
Europe PubMed Central
PubMed publication ID
21126685
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21126685%20AND%20SRC:MED&resulttype=core&format=json
retrieved
17 January 2020
cites work
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970259-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970259-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970259-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Progression-free survival: gaining on overall survival as a gold standard and accelerating drug development
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970259-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Overall survival: a gold standard in search of a surrogate: the value of progression-free survival and time to progression as end points of drug efficacy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970259-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Progression-free survival is simply a measure of a drug's effect while administered and is not a surrogate for overall survival.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970259-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Stable disease is not preferentially observed with targeted therapies and as currently defined has limited value in drug development.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970259-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970259-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Identifiers
DOI
10.1016/S1470-2045(10)70259-X
1 reference
stated in
Europe PubMed Central
PubMed publication ID
21126685
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21126685%20AND%20SRC:MED&resulttype=core&format=json
retrieved
17 January 2020
PubMed publication ID
21126685
1 reference
stated in
Europe PubMed Central
PubMed publication ID
21126685
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21126685%20AND%20SRC:MED&resulttype=core&format=json
retrieved
17 January 2020
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit